Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Status:
Completed
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
A study to evaluate the effect of erenumab compared to placebo on the change from baseline in
monthly migraine days in participants with episodic migraine.